Jovana Milic, Alessio Novella, Marianna Meschiari, Marianna Menozzi, Antonella Santoro, Andrea Bedini, Gianluca Cuomo, Erica Franceschini, Margherita Digaetano, Federica Carli, Giacomo Ciusa, Sara Volpi, Erica Bacca, Giacomo Franceschi, Dina Yaacoub, Carlotta Rogati, Marco Tutone, Giulia Burastero, Matteo Faltoni, Vittorio Iadisernia, Giovanni Dolci, Andrea Cossarizza, Cristina Mussini, Luca Pasina, Giovanni Guaraldi
Background The aim of this study was to evaluate both positive outcomes, including reduction of respiratory support aid and duration of hospital stay, and negative ones, including mortality and a composite of invasive mechanical ventilation or death, in patients with COVID-19 pneumonia treated with or without oral darunavir/cobicistat (DRV/c, 800/150 mg/day) used in different treatment duration. Secondary objective was to evaluate the percentage of patients treated with DRV/c who were exposed to potentially severe drug-drug interactions (DDI) and died during hospitalization...
February 23, 2021: AIDS Research and Human Retroviruses